country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-164702

Copy Link Print Information

BL-B01D1

Name: BL-B01D1
Brand: MedChemExpress
SKU: HY-164702
Price: 1450.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Izalontamab Brengitecan)

Revisión del cliente

Based on 1 Customer Validation

BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 96.38%
Peso molecular:205830.00

Almacenamiento:

-80°C, protect from light

BL-B01D1 Chemical Structure

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vivo
- Ensayo clínico
Chemical Information
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]

Topoisomerase I

EGFR

HER3

Ver todos los productos específicos de isoformas EGFR :

Ver todos los productos específicos de isoformas Topoisomerase :

In Vivo

BL-B01D1 (Izalontamab Brengitecan) exhibits superior in vivo antitumor activity compared to single-target EGFR or HER3 antibody-drug conjugates in cancer-patient-derived tumor xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Liquid
Peso molecular 205830.00
Color Colorless to light yellow
SMILES

[BL-B01D1]
Synonyms

Izalontamab Brengitecan
Envío

Shipping with dry ice.
Almacenamiento

-80°C, protect from light

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Wan W, et al. Abstract 2642: BL‑B01D1, a novel EGFR×HER3‑targeting ADC, demonstrates robust anti‑tumor efficacy in preclinical evaluation. Cancer Research. 2023 Apr 4;83(7_Supplement):2642.

[2]. Liu C, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025 Oct;31(10):3485-3491.

[3]. Ma Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911. [Content Brief]

[4]. Bian X, et al. Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Nov 10;43(32):3505-3515.

[5]. Zhang L, et al. BL‑B01D1, a first‑in‑class EGFR×HER3 bispecific antibody‑drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first‑in‑human phase 1 study. Journal of Clinical Oncology. 2023 Jun;41(16_suppl):3001.

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto

Amount: USD 0.00

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vivo
- Ensayo clínico
Chemical Information
Pureza y Documentación
Referencias

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

BL-B01D1

Ver todos los productos específicos de isoformas EGFR

Ver todos los productos específicos de isoformas Topoisomerase